

**Efficacy of Cardiac Myosin Inhibitors in Symptomatic Hypertrophic
Cardiomyopathy: A Meta-Analysis Update and Systematic Review**

Journal name: IJCS.

Supplementary Table 1. Search strategy.

Pubmed	(cardiac myosin inhibitor OR Aficamten OR CK-274 OR Mavacamten OR MYK-461 OR Camzyos) AND (HCM OR oHCM OR HOCM Hypertrophic cardiomyopathy OR Cardiomyopathy, hypertrophic OR Cardiomyopathy, hypertrophic [mh] OR cardiomyopathies, hypertrophic OR Hypertrophic Cardiomyopathies)
Embase	(cardiac myosin inhibitor OR Aficamten OR CK-274 OR Mavacamten OR MYK-461 OR Camzyos) AND (HCM OR oHCM OR HOCM Hypertrophic cardiomyopathy OR Cardiomyopathy, hypertrophic OR Cardiomyopathy, hypertrophic OR cardiomyopathies, hypertrophic OR Hypertrophic Cardiomyopathies)
Cochrane	(cardiac myosin inhibitor OR Aficamten OR CK-274 OR Mavacamten OR MYK-461 OR Camzyos) AND (HCM OR oHCM OR HOCM Hypertrophic cardiomyopathy OR Cardiomyopathy, hypertrophic OR Cardiomyopathy, hypertrophic OR cardiomyopathies, hypertrophic OR Hypertrophic Cardiomyopathies)


Supplementary Table 2.

Study	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcomes	Selection of the reported results	Overall risk of bias
EXPLORER-CN 2023	Some concerns	Low	Low	Low	Low	Some concerns
EXPLORER-HCM 2020	Low	Low	Low	Low	Low	Low
MAVERICK-HCM 2020	Some concerns	Low	Low	Low	Low	Some concerns
REDWOOD-HCM 2023	Low	Low	Low	Low	Low	Low
SEQUOIA-HCM 2024	Low	Low	Low	Low	Low	Low
VALOR-HCM 2022	Low	Low	Low	Low	Low	Low

Supplementary Table 2. Critical appraisal of individual studies according to the Cochrane


Collaboration's tool for assessing risk of bias in randomized trials.

Supplementary Figure 1.




Supplementary Figure 1. Sensitivity analysis of Improvement of at least one NYHA functional class to identify sources of heterogeneity. CI, confidence interval; CMI, cardiac myosin inhibitor

Supplementary Figure 2.




Supplementary Figure 2. Sensitivity analysis of Change from baseline in KCCQ-CSS to identify sources of heterogeneity. MD, mean difference; SE, standard error; CI, confidence interval; CMI, cardiac myosin inhibitor

Supplementary Figure 3.




Supplementary Figure 3. Sensitivity analysis of change from baseline in LVOT after Valsalva maneuver to identify sources of heterogeneity. MD, mean difference; SE, standard error; CI, confidence interval; CMI, cardiac myosin inhibitor

Supplementary Figure 4.



Supplementary Figure 4. Sensitivity analysis of change from baseline in LVOT at rest to identify sources of heterogeneity. MD, mean difference; SE, standard error; CI, confidence interval; CMI, cardiac myosin inhibitor


Supplementary Figure 5.



Supplementary Figure 5. Subgroup analysis of including only patients with symptomatic obstructive HCM.

Improvement of at least one NYHA classification in oHCM. CI, confidence interval; CMI, cardiac myosin inhibitor

Supplementary Figure 6.



Supplementary Figure 6. Subgroup analysis of including only patients with symptomatic obstructive HCM.

Change from baseline in KCCQ-CCS in oHCM. MD, mean difference; SE, standard error; CI, confidence interval;

CMI, cardiac myosin inhibitor